You are here

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

depressive disorder based on DSM-IV criteria, with/without current co-morbid anxiety
disorder; 4. Has two or more episodes of depression (including the current episode) in the
past 5 years, with an interval of at lease 2 months between the end of the previous episode
and the beginning of the current episode. 5. The baseline score of 17-item Hamilton Rating
Scale for Depression (HAM-D)>=17; 6 If female of childbearing potential, have a negative
urine pregnancy test at baseline, if appropriate, and use a medically acceptable method of
contraception throughout the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

before;3.Clinically significant renal or hepatic disease or any other medical disease that,
in the opinion of the investigator, might compromise the study, including seizure disorder
(with the exception of a single childhood febrile seizure); 4.Alcohol or drug abuse within
the last year;5.A recent history of myocardial infarction or unstable heart disease (within
6 months of baseline);6.Bipolar disorder;7.For female, known or suspected pregnancy or
breast feeding;8.Use of a monoamine oxidize inhibitor (MAOI) within 14 days of baseline;
use of any investigational drug within 30 days of baseline.

NCT00878748
Pfizer
Withdrawn
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Obsessive Compulsive Disorder
NCT01302080
All Genders
6+
Years
Multiple Sites
Major Depressive Disorder
NCT02548949
All Genders
19+
Years
Multiple Sites
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: Effexor XR
  • Other: Effexor XR discontinue
  • Experimental: A
    Effexor XR
    Intervention: Drug: Effexor XR
  • B
    Effexor XR discontinue
    Intervention: Other: Effexor XR discontinue
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion criteria: 1. Males or females, 18 years of age or more; 2. Outpatients; 3. Major depressive disorder based on DSM-IV criteria, with/without current co-morbid anxiety disorder; 4. Has two or more episodes of depression (including the current episode) in the past 5 years, with an interval of at lease 2 months between the end of the previous episode and the beginning of the current episode. 5. The baseline score of 17-item Hamilton Rating Scale for Depression (HAM-D)>=17; 6 If female of childbearing potential, have a negative urine pregnancy test at baseline, if appropriate, and use a medically acceptable method of contraception throughout the study.

Exclusion criteria:1.Hypersensitivity to venlafaxine;2.Received venlafaxine treatment before;3.Clinically significant renal or hepatic disease or any other medical disease that, in the opinion of the investigator, might compromise the study, including seizure disorder (with the exception of a single childhood febrile seizure); 4.Alcohol or drug abuse within the last year;5.A recent history of myocardial infarction or unstable heart disease (within 6 months of baseline);6.Bipolar disorder;7.For female, known or suspected pregnancy or breast feeding;8.Use of a monoamine oxidize inhibitor (MAOI) within 14 days of baseline; use of any investigational drug within 30 days of baseline.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00878748
0600X1-4434
Yes
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
September 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now